Drug Pricing
Our work in Drug Pricing
-
Effect of Oral Nutritional Supplements On Hospital Outcomes in Patients Aged 65+ With Congestive Heart Failure
This study found that, in elderly patients hospitalized with congestive heart failure, oral nutritional supplement use could provide a low-cost strategy for improving hospitalization outcomes for elderly patients and reducing the burden on health systems.
Categorized in -
Is Reducing Specialty Drugs Coverage Penny-Wise, but Pound Foolish?
Specialty drugs are a complicated component of pharmaceutical spending because they offer substantial benefits to a select group of people with complicated drug and medical needs but they have very high tags.
Categorized in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Categorized in -
Lack of Price Transparency: Extreme Variations in Costs for Brand Name and Generic Prescription Drugs as a Barrier for Uninsured Patients
This paper discusses whether prescribing drugs with a generic formulation will save hospital outpatients money and consequently increase compliance.
Categorized in -
Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?
The researchers analyzed the effects of oral nutritional supplement (ONS) use on 30-day readmission rates, length of stay (LOS), and episode costs in hospitalized Medicare patients (≥65), and subsets of patients diagnosed with acute myocardial infarction (AMI), congestive heart failure (CHF) or pneumonia (PNA), finding that ONS use was associated with improved outcomes and decreased healthcare costs, and is therefore relevant to providers seeking an inexpensive, evidence-based approach for meeting Affordable Care Act quality targets.
Categorized in -
Association Between Availability of Health Service Prices and Payments for These Services
The researchers determined whether the use of an employer-sponsored private price transparency platform was associated with lower claims payments for three common medical services and found that patient access to pricing information before obtaining clinical services may result in lower overall payments made for clinical care.
Categorized in -
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
This study compared the cost-effectiveness of fingolimod, teriflunomide, dimethyl fumarate, and intramuscular interferon-β1a as first-line therapies in the treatment of patients with relapsing-remitting multiple sclerosis.
Categorized in -
Five Myths about Cancer Care in America
Dana Goldman and Tomas Philipson highlight the consequence of common myths about cancer care including drawing the public’;s attention away from the
real story.Categorized in -
The Cost and Value of Biomedical Innovation: Implications for Health Policy
High-cost drugs and devices that address significant unmet medical needs have generated much attention lately. New treatments for many cancers and for infections like Hepatitis C have the potential to increase life expectancy and quality of life for affected patients. Many more such treatments are in development. While a number of important breakthroughs have occurred […]
Categorized in -
Are Investments in Disease Prevention Complements? The Case of Statins and Health Behaviors
The researchers obtained estimates of associations between statin use and health behaviors and found that statin use was associated with increased physical activity among males and that statin use increased the use of blood pressure medication and aspirin for both males and females.
Categorized in